FOREWORD Multiple sclerosis therapeutics: opportunities, strategies and challenges
نویسنده
چکیده
1994). 4. PRISMS Study Group: Randomiseddouble-blind placebo-controlled study of interferon β-1a in relapsing/remittingmultiple sclerosis. PRISMS (Prevention ofRelapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) StudyGroup [see comments]. Lancet 352,1498–1504 (1998).5. Johnson KP, Brooks BR, Cohen JA et al.:Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a Phase IIImulticenter, double-blindplacebo-controlled trial. Neurology 45, 1268–1276 (1995).6. Jacobs LD, Beck RW, Simon JH et al.:Intramuscular interferon β-1a therapy initiated during a first demyelinating eventin multiple sclerosis. CHAMPS StudyGroup. N. Engl. J. Med. 343, 898–904 (2000).7. Filippi M, Rovaris M, Inglese M et al.:Interferon β-1a for brain tissue loss in patients at presentation with syndromessuggestive of multiple sclerosis:a randomised, double-blind,placebo-controlled trial. Lancet 364,1489–1496 (2004).8. Kappos L, Polman CH, Freedman MS et al.:Treatment with interferon β-1b delaysconversion to clinically definite and McDonald MS in patients with clinicallyisolated syndromes. Neurology 67,1242–1249 (2006). 9. Polman CH, O'Connor PW, Havrdova Eet al.: A randomized, placebo-controlledtrial of natalizumab for relapsing multiplesclerosis. N. Engl. J. Med. 354, 899–910(2006). 10. Cofield SS, Cutter GR: Novel designs for clinical trials in multiple sclerosis – anotherexcursion to Sirenum scopuli? Therapy 5(5),613–622 (2008). 11. Comabella M: Pharmacogenomics inmultiple sclerosis: getting the right medicineto the right patient. Therapy 5(5), 623–629 (2008).12. Comabella M, Espejo C, Sastre-Garriga J,Rio J: Research highlights. Therapy 5(5),
منابع مشابه
P 53: Stem Cell Therapy for Treatment of Autoimmune Diseases (with Emphasis on Multiple Sclerosis)
Autoimmune diseases have been described as an interesting and poorly understood group of disorders. There are many challenges in the respective scientific societies concerning the nature, causes and the therapeutic approaches of these diseases. In accordance with the evidences the nature and etiology of these disorders is multifactorial and complex but the clearest definition could be expressed...
متن کاملSocial Support Needs of Iranian Family Caregivers of Multiple Sclerosis Patients: A Qualitative Study
Aim: Multiple sclerosis (MS) is one of the most common chronic progressive neurological diseases and is regarded as the non-traumatic cause of neurological disability in youth. The Multiple sclerosis patients need for family caregiver increasingly grows due to the progressive course of the disease, which worsens the symptoms over time. Family caregivers of this group of patients are subject to ...
متن کاملComparing early maladaptive schemas, emotional regulation and coping strategies in patients with multiple sclerosis and healthy people
The purpose of this study was to investigate and compare maladaptive schemas and emotional regulation and coping strategies in patients with multiple sclerosis and healthy individuals. The statistical population of all individuals with multiple sclerosis was Sina Hospital in Tehran (1966-1393). Of these, 202 patients were selected from 102 patients with multiple sclerosis and 100 healthy subjec...
متن کاملP122: Small Molecules as Chemical and Pharmacological Tools for Neuroinflammatory Diseases Treatment (with Emphasis on Multiple Sclerosis)
Multiple Sclerosis (MS) is a neuroinflammatory disease resulting in degeneration of the myelin sheaths and death of oligodendrocytes. So far, several strategies have been introduced to control the disease. Treatment with small molecules is one of the strategies that have recently attracted the attention in the scientific community. These molecules that target epigenetic and other cellular proce...
متن کامل